Needle-free injection technology company PharmaJet said on Thursday that it has signed a Memorandum of Understanding with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma to explore the integration of needle-free delivery for inactivated polio vaccines into Egypt's national immunisation programme.

The agreement includes provisions for product distribution, localised manufacturing, technology transfer, and pharmaceutical development aimed at expanding needle-free access in Egypt and the broader region.

The UPA intends to use new technologies to reduce total immunisation costs, enhance pandemic preparedness, and strengthen foreign exchange positions. PharmaJet's Tropis needle-free system is expected to generate immunisation cost savings of 38% or more over six years, while increasing vaccine coverage and reducing hesitancy.

This collaboration supports Egypt's Universal Health Insurance project and builds on the goals of the '1000 Golden Days' presidential initiative targeting early childhood health.

PharmaJet's Tropis device has already been used in polio campaigns and has demonstrated over 94% acceptability among healthcare providers and caregivers, along with a 50% reduction in adverse events compared to needle-based delivery.

The initiative positions Egypt to become a regional hub for needle-free immunisation manufacturing and innovation across the Middle East and Northern Africa.